SOLID CANCERS

This early-stage trial tests a treatment called Anti-CEA CAR-T, which uses a patient's own immune cells modified to recognize and attack cancer cells that carry a protein called CEA. The study enrolls about 110 adults with advanced colorectal, gastric, or other solid tumors that …

This phase 2 trial tests a new radiation technique called lattice radiation therapy (LRT) combined with immunotherapy in 30 people with advanced solid tumors that have not responded to standard treatments. LRT delivers high doses of radiation to small spots inside the tumor while…

This early-stage trial is testing a new type of immune cell therapy called armored dendritic cells in 8 people with solid cancers like pancreatic or colorectal cancer. Participants have already had surgery and at least 4 rounds of chemotherapy. The goal is to see if the treatment…

This study tests a new drug called TCC1727 combined with other medicines (benmelstobart, olaparib, or topotecan) in people with advanced solid tumors, including lung, stomach, endometrial cancer, and melanoma. The goal is to find the safest dose and see if the combination helps s…

This study tests an experimental drug called tunlametinib in 15 people with advanced solid tumors (not melanoma) that have a mutation in the NRAS gene and have not responded to other treatments. The drug is taken as a capsule twice a day in 21-day cycles. The main goal is to see …

This study looks at whether using a weighted blanket during intravenous cancer treatment can help lower anxiety, stress, and depression, and improve comfort. About 152 adults with solid cancers who are starting their first IV therapy will be randomly assigned to receive either a …

This study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …

This study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…

This study is testing whether a new tool called xDRIVE, which combines artificial intelligence and tumor profiling, can quickly suggest personalized treatment options for cancer patients in Florida whose cancer has come back or not responded to standard treatments. The goal is to…